Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Orasis Pharmaceuticals
company
About
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia as an alternative to reading glasses.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $13M
- Industries
- Clinical Trials,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$43M
Orasis Pharmaceuticals has raised a total of
$43M
in funding over 2 rounds. Their latest funding was raised on
Sep 10, 2020 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 10, 2020 | Series C | $30M | 1 | — | — | Detail |
| Jun 5, 2018 | Series B | $13M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Orasis Pharmaceuticals is funded by 1 investors.
Sequoia Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sequoia Capital
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
